Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up.
Anemia
Erythropoietin resistance index
Ferric carboxymaltose
Hemodialysis
Journal
Kidney research and clinical practice
ISSN: 2211-9132
Titre abrégé: Kidney Res Clin Pract
Pays: Korea (South)
ID NLM: 101586778
Informations de publication
Date de publication:
30 Sep 2020
30 Sep 2020
Historique:
received:
24
01
2020
revised:
07
05
2020
accepted:
10
05
2020
pubmed:
26
8
2020
medline:
26
8
2020
entrez:
26
8
2020
Statut:
ppublish
Résumé
Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed. The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study. FCM increased transferrin saturation (TSAT) levels by 11.9% ( During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT.
Sections du résumé
BACKGROUND
BACKGROUND
Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed.
METHODS
METHODS
The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study.
RESULTS
RESULTS
FCM increased transferrin saturation (TSAT) levels by 11.9% (
CONCLUSION
CONCLUSIONS
During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT.
Identifiants
pubmed: 32839355
pii: j.krcp.20.015
doi: 10.23876/j.krcp.20.015
pmc: PMC7530360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
334-343Références
Nephrol Dial Transplant. 2011 May;26(5):1599-607
pubmed: 20929915
Nephrol Dial Transplant. 2013 Apr;28(4):953-64
pubmed: 23222534
N Engl J Med. 2006 Nov 16;355(20):2085-98
pubmed: 17108343
Nephrol Dial Transplant. 2014 Nov;29(11):2075-84
pubmed: 24891437
Pharmacotherapy. 2004 May;24(5):574-83
pubmed: 15162891
Nephrol Dial Transplant. 2014 Apr;29(4):833-42
pubmed: 23963731
Am J Kidney Dis. 2001 Jan;37(1 Suppl 1):S182-238
pubmed: 11229970
J Am Soc Nephrol. 2004 Dec;15 Suppl 2:S93-8
pubmed: 15585603
N Engl J Med. 2009 Nov 19;361(21):2019-32
pubmed: 19880844
Semin Dial. 2009 Jan-Feb;22(1):70-7
pubmed: 19250447
Pharmaceutics. 2011 Jan 04;3(1):12-33
pubmed: 24310424
Nephrol Dial Transplant. 2010 Aug;25(8):2722-30
pubmed: 20190247
Drugs. 2009;69(6):739-56
pubmed: 19405553
J Am Soc Nephrol. 2009 Jul;20(7):1453-64
pubmed: 19478096
Am J Nephrol. 2017;45(1):49-59
pubmed: 27889746
J Bone Miner Res. 2013 Aug;28(8):1793-803
pubmed: 23505057
BMC Nephrol. 2018 Sep 20;19(1):242
pubmed: 30236065
N Engl J Med. 2019 Jan 31;380(5):447-458
pubmed: 30365356
Curr Opin Nephrol Hypertens. 2017 Jul;26(4):266-275
pubmed: 28399017
Nephrol Dial Transplant. 2006 Apr;21(4):991-8
pubmed: 16384825
Am J Kidney Dis. 2007 Sep;50(3):471-530
pubmed: 17720528
Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):133-141
pubmed: 30839153
N Engl J Med. 2006 Nov 16;355(20):2071-84
pubmed: 17108342